Back to Results
First PageMeta Content
Viral diseases / Hepatology / Hepatitis / Viral hepatitis / Hepatitis C / Hepatocellular carcinoma / Ribavirin / Hepatitis B / Antiviral drug / Medicine / Health / Biology


SPECIAL FEATURE Hepatitis C: everyone deserves a chance at cure Michael W. Fried, MD, Director, UNC Liver Center New all-oral therapies for hepatitis C can permanently cure over 90 percent of infections in the United St
Add to Reading List

Document Date: 2014-10-20 04:33:43

Open Document

File Size: 1,44 MB

Share Result on Facebook

Company

Merck / Vertex / Genentech / Bristol-Myers Squibb / /

Country

United States / /

Facility

University of North Carolina / Chapel Hill / /

IndustryTerm

treatment of hepatitis C / Treatment of HCV / HCV care / therapies for hepatitis C / HCV therapeutics / /

MedicalCondition

HIV infection / hepatic fibrosis / chronic viral disease / HIV / viral infection / headache / HCV genotype 1 / patient outcomes Hepatitis C / liver failure / hepatocellular carcinoma / chronic liver disease / SPECIAL FEATURE Hepatitis C / nausea / cirrhosis / hepatitis C / HCV / HCV infection / fatigue / hepatitis C. SVR / virus infection / diseases / infection / viral hepatitis / infections / anemia / Chronic hepatitis C / HCV RNA / /

MedicalTreatment

blood transfusion / Retreatment / oral therapies / hemodialysis / body piercing / organ transplant / organ transplants / antiviral therapy / /

NaturalFeature

Chapel Hill / /

Organization

UNC Liver Center / FDA / University of North Carolina / Chapel Hill / U.S. Preventative Services Task Force / U.S. Centers for Disease Control and Prevention / /

Person

Children / Michael W. Fried / /

Position

ad hoc consultant / Director / General / professor of medicine / /

Product

ribavirin / /

ProvinceOrState

North Carolina / /

Technology

genotype / /

SocialTag